NASDAQ : ELOX
Eloxx Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 13.45 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 54.29M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 54.29M |
| Enterprise Value | 4.16M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 4.04M |
| Shares Outstanding | 4.04M |
| Shares Change (YoY) | +1,502.77% |
| Shares Change (QoQ) | +54.91% |
| Owned by Insiders (%) | 3.84% |
| Owned by Institutions (%) | 13.73% |
| Float | 932,567 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.17 |
| P/TBV Ratio | 1.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.74 |
| Quick Ratio | 3.65 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -40.41 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -25.59% |
| Weighted Average Cost of Capital (WACC) | -773,614.98% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.07M |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -171,310.26 |
| 52-Week Price Change | +1,222,627.27% |
| 50-Day Moving Average | 15.34 |
| 200-Day Moving Average | 7.92 |
| Relative Strength Index (RSI) | 45.46 |
| Average Volume (20 Days) | 25,462 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 41,345 |
| Short Previous Month | 53,935 |
| Short % of Shares Out | 1.02% |
| Short % of Float | 4.43% |
| Short Ratio (days to cover) | 1.74 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.88M |
| Pretax Income | -10.65M |
| Net Income | -10.65M |
| EBITDA | n/a |
| EBIT | -11.88M |
| Earnings Per Share (EPS) | -$2.84 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 61.96M |
| Total Debt | 11.83M |
| Net Cash | 50.13M |
| Net Cash Per Share | $12.42 |
| Equity (Book Value) | 46.42M |
| Book Value Per Share | 11.50 |
| Working Capital | 46.42M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -16.02M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | 300,000 |
| Free Cash Flow | -16.02M |
| FCF Per Share | -$3.97 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1,502.77% |
| Shareholder Yield | -1,502.77% |
| Earnings Yield | -21.14% |
| FCF Yield | -29.51% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $37.50 |
| Price Target Difference | 178.81% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 1, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:11 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |